Our previous analyses in this BC cohort (n = 622) revealed that sustained tumor cell proliferation after preoperative endocrine therapy (defined as post-pET Ki67 ≥10%) was associated with TP53 mutation but not with ERBB2 mutation23. This evidence concerns the gene TP53 and breast cancer.